RecruitingPhase 3NCT06534723

Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Principal Investigator
Xiaochun Chen, Medical Doctor
Fujian Medical University Affiliated Union Hospital
Intervention
Wujia Yizhi granules(drug)
Enrollment
570 target
Eligibility
50-80 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06534723 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease

← Back to all trials